Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.
Zhao X et al.
Translational Lung Cancer Research, 2025
Acquired multiple EGFR mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review.
Yang F et al.
Oncology Letters, 2025
Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities.
Zhang H et al.
Elife, 2024
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18.
Zhang Y et al.
Translational Lung Cancer Research, 2024
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort.
Bruno R et al.
Cancers, 2024
Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
Burr R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.
Pretelli G et al.
International Journal of Molecular Sciences, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.
Villaruz LC et al.
Esmo Open, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H et al.
Frontiers in Oncology, 2022
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.
Wei J et al.
Targeted Oncology, 2021
RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma.
Liu B et al.
Frontiers in Oncology, 2021
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.
Wu SG et al.
Therapeutic Advances in Medical Oncology, 2020
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM et al.
Lung Cancer (amsterdam, Netherlands), 2017
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A et al.
Genome Medicine, 2016
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Kim EY et al.
Cancer Biology & Therapy, 2016
EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.
Cheng C et al.
Scientific Reports, 2015
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
Paz-Ares L et al.
Journal of Cellular and Molecular Medicine, 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Tseng JS et al.
Plos One, 2014
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
Paz-Ares L et al.
Journal of Cellular and Molecular Medicine, 2010
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG et al.
The Oncologist, 2008
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Kimura H et al.
British Journal of Cancer, 2007